Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Theraclone Sciences has started subject dosing in Phase 1 trial evaluating the safety profile of intravenous administration of TCN-202 as compared to placebo in healthy adult volunteers.
Subscribe to our email newsletter
The TCN-202 is an antibody in development for the treatment of human cytomegalovirus (CMV) infection.
Theraclone Sciences CEO Clifford Stocks said TCN-202 was discovered using Theraclone’s I-STAR platform, which has demonstrated an ability to identify natural human antibodies with broad biologic activity and therapeutic potential.
"TCN-202 is directed against what we believe is a universal target within CMV variations, and this Phase 1 study is a significant step in bringing an important new treatment to patients with CMV infection," Stocks added.
The randomised study will provide safety, pharmacokinetic and immunogenicity data.
The double-blinded study will enrol up to 80 normal healthy volunteers at a single site in the US.
Theraclone anticipates study results in the first half of 2013.